Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 2;20(2):389–397. doi: 10.1158/1535-7163.MCT-20-0632

Figure 3. Pre-treatment CD8+ T cell profiles in the peripheral blood associate with outcomes to galunisertib and radiation.

Figure 3.

Baseline PBMC samples were analyzed by high-dimensional single cell profiling using mass cytometry. (A) Shown is phenograph clustering analysis performed after the exclusion of doublets, dead cells and CD19 cells and positive selection for CD45, CD3 and CD8. (B) PCA analysis of phenograph defined CD8+ clusters. (C) Stacked bar graph showing manually gated CD8+ naïve (CCR7+CD45ROneg), effector (CCR7negCD45ROneg), effector memory (CCR7negCD45RO+) and central memory (CCR7+CD45RO+) cell frequencies in individual patients. (D) Effector (CCR7negCD45ROneg) to naïve (CCR7+CD45ROneg) CD8+ T cell ratio at baseline among Progressors and Non-Progressors. Mann-Whitney tests were performed. *, p < 0.05. NE, not evaluable. NP, Non-Progressor. P, Progressor. EM, effector memory. CM, central memory.